2016 AAFP Feline Hyperthyroidism Guidelines: Six Clinical Categories and Treatment Algorithm

Bottom line.

• The 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism (Carney et al., J Feline Med Surg 18:400–416) organize diagnosis into six clinical categories — from overt hyperthyroidism to the clinically occult presentation — each with a defined management strategy.¹
• The guidelines identify four treatment modalities (radioiodine, thyroidectomy, antithyroid drugs, iodine-restricted diet) and rank radioiodine as the preferred definitive therapy for most cats; antithyroid drugs remain the most widely used because of accessibility.¹
• A key guideline recommendation is a pre-treatment or pre-referral methimazole trial (minimum 4 weeks) for cats with suspected concurrent CKD, to assess renal function after restoration of euthyroidism before committing to an irreversible treatment.¹
• The guidelines state that treatment should not be withheld on the basis of comorbidities — including CKD and hypertrophic cardiomyopathy — because untreated hyperthyroidism is itself harmful; individualized monitoring is required.¹
• This is a clinician-facing evidence summary. It is not a dosing protocol; refer to the full published guidelines for the complete treatment algorithm.

Update context

The 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism (published J Feline Med Surg May 2016) remain the current consensus document governing the diagnosis and management of feline hyperthyroidism in North America. This update summarizes the treatment algorithm and key decision points for the general practitioner.

Managing a hyperthyroid cat?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk integrates the 2016 AAFP guidelines alongside current formularies.

Try Voyage Clinical Desk

What the evidence shows

The six clinical categories

The guidelines divide feline hyperthyroid presentations into six categories to guide diagnostic and therapeutic decision-making:¹

1. Classic overt hyperthyroidism: Serum TT4 above the reference interval with compatible clinical signs. Diagnose and treat.
2. Mildly elevated TT4 in a clinically ill cat: Elevated T4 may reflect non-thyroidal illness (NTI); repeat testing after resolution of NTI or perform additional thyroid function testing (free T4 by equilibrium dialysis, TSH).
3. High-normal TT4 with compatible clinical signs: TT4 in the upper quarter of the reference range with compatible signs; perform free T4 and TSH, or repeat TT4 in 4–6 weeks.
4. Occult (masked) hyperthyroidism — elevated T4 in a clinically normal cat: Confirm and monitor; consider treatment if T4 rises or clinical signs develop.
5. Hyperthyroid cat with concurrent CKD: A methimazole trial is strongly recommended before irreversible treatment.
6. Hyperthyroid cat with concurrent cardiac disease: Treat hyperthyroidism promptly; cardiac abnormalities may partially resolve with euthyroidism.

The four treatment modalities

The 2016 AAFP guidelines describe four treatment options:¹

Radioiodine (¹³¹I): Endorsed by the guidelines as the preferred treatment for most hyperthyroid cats because it is permanently curative, does not require anesthesia, and avoids the need for lifelong daily medication. Practical barriers (licensed facility, isolation requirement, cost of $1,000–$2,000) limit access.

Thyroidectomy: Curative if complete; historically the primary treatment before I-131 became widely available. Carries anesthetic risk in geriatric cats and risk of hypoparathyroidism; now rarely performed as first choice.

Antithyroid drugs (methimazole/carbimazole): Most accessible and widely used; provides control but not cure. Long-term daily administration required. Recommended as the default medical option and as a bridge to definitive therapy.

Iodine-restricted diet (Hill's Prescription Diet y/d): Can normalize TT4 in cats that eat the diet exclusively. Practical challenges include palatability and the inability of multi-cat households to ensure exclusivity. The guidelines note this option is appropriate for select cats but requires careful monitoring.

The concurrent CKD decision pathway

The guidelines give detailed guidance on the hyperthyroid-CKD interface:¹

• Hyperthyroidism-induced high cardiac output elevates GFR, masking underlying CKD in a substantial proportion of cats (estimated 15–50%).
• Restoration of euthyroidism unmasks pre-existing CKD by reducing GFR and raising serum creatinine.
• The guidelines recommend a 4-week methimazole trial before irreversible treatment (I-131 or surgery) to reveal the degree of masked azotemia.
• If azotemia develops during the methimazole trial, the dose should be reduced to the lowest dose that maintains TT4 in the low-normal range rather than stopping treatment; untreated hyperthyroidism is also damaging to the kidneys and other organs.
• There is no evidence that withholding treatment benefits cats with concurrent CKD; the guidelines state that all hyperthyroid cats, regardless of comorbidities, should be treated.

Monitoring the treated cat

The guidelines recommend monitoring to avoid exacerbating comorbid disease:¹

• Recheck TT4, CBC, serum chemistry (including creatinine), and blood pressure 2–4 weeks after initiating methimazole.
• After dose adjustments, recheck TT4 in 4 weeks.
• Once stable, recheck every 3–6 months.
• TT4 target: low-normal range (1.0–2.5 µg/dL); persistently suppressed TT4 (<1.0 µg/dL) risks unmasking severe azotemia.

How this fits clinical practice

The 2016 AAFP guidelines provide a practical framework that replaces the binary "treat or don't treat" approach with nuanced case categorization. The most clinically actionable guidance for general practitioners is: (1) always screen pre-treatment for azotemia, cardiac disease, and hypertension; (2) perform a methimazole trial before I-131 or surgery if CKD is suspected; (3) target TT4 in the low-normal range rather than aggressive suppression; and (4) do not withhold treatment because of comorbidities. Always refer to the full published guidelines (Carney et al. 2016, J Feline Med Surg 18:400–416) for the complete diagnostic algorithm and management tables.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Carney HC, Ward CR, Bailey SJ, Bruyette D, Dennis S, Ferguson D, Hinc A, Rucinsky AR. 2016. 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism. J Feline Med Surg 18(5):400–416. https://pubmed.ncbi.nlm.nih.gov/27143042/
2. Lucy JM, Peterson ME, Randolph JF, Scrivani PV, Rishniw M, Davignon DL, Thompson MS, Scarlett JM. 2017. Efficacy of Low-dose versus Standard-dose Radioiodine Treatment for Cats with Mild-to-Moderate Hyperthyroidism. J Vet Intern Med 31(2):326–334. https://pubmed.ncbi.nlm.nih.gov/28158908/
3. Peterson ME, Kintzer PP, Hurvitz AI. 1988. Methimazole treatment of 262 cats with hyperthyroidism. J Vet Intern Med 2(3):150–157. https://pubmed.ncbi.nlm.nih.gov/3265728/

Changelog

• 2026-06-28: First published.